Immatics (IMTX) AI Stock Analysis

• Market Cap: $745.10M
• Dividend Yield: N/A
• Average Volume (3M): 653.26K
• Price to Earnings (P/E): 53.8
• Beta (1Y): 1.68
• Revenue Growth: 92.31%
• EPS Growth: 78.17%
• Country: US
• Employees: 554
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 121,550,170
• 10 Day Avg. Volume: 369,563
• 30 Day Avg. Volume: 653,257
• PEG Ratio: 0.17
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.50
• Price Target Upside: 87.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 58 Neutral
• Price Target: $6.00 ▼(-2.12%Downside)

Immatics shows a promising equity position and short-term technical momentum, but faces significant challenges with profitability and cash flow. The lack of a positive P/E ratio further weighs down the valuation.

Positive Factors

Clinical Trials

IMTX presented updated Phase Ib data for IMA203, which is viewed as encouraging and further supports its development in melanoma.

Pipeline Development

IMTX is considered a leader in TCR therapeutics and is attractively valued with a broad platform encompassing both TCR T-cell therapy and TCR bispecifics.

Negative Factors

Enrollment Challenges

IMTX confirmed that the Phase III SUPRAME study evaluating IMA203 in cutaneous melanoma has started to enroll patients and remains on track to complete enrollment by the end of 2026, indicating potential delays in reaching study milestones.

Immatics Business Overview & Revenue Model

Company Description

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

How the Company Makes Money

Immatics generates revenue through strategic collaborations and partnerships with pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the development, commercialization, and licensing of its immunotherapy products. Immatics also invests in the research and development of its pipeline products, aiming to bring them to market either independently or through partnerships, contributing to future revenue streams. Additionally, government grants and funding for research initiatives may supplement its revenue generation efforts.

Immatics Financial Statement Overview

Summary

Immatics demonstrates potential with strong revenue growth in certain periods and a solid equity position. However, persistent profitability and cash flow challenges pose risks. The reliance on external financing could impact long-term sustainability if operational improvements are not realized.

Income Statement

Immatics has shown volatile revenue growth, with a significant increase from 2023 to 2024 but a decline in TTM. The gross profit margin is strong, indicating effective cost management, but the company struggles with negative net and EBIT margins, highlighting ongoing profitability challenges.

Balance Sheet

The company maintains a robust equity position with an impressive equity ratio, suggesting stability. The debt-to-equity ratio is low, indicating conservative leverage practices. However, the company has experienced fluctuations in stockholders' equity, which may impact future stability.

Cash Flow

Immatics faces challenges with negative operating and free cash flows, indicating cash management issues. The operating cash flow to net income ratio suggests inefficiencies in converting income to cash. Positive financing cash flow reflects a reliance on external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	155.84M	54.00M	172.83M	34.76M	31.25M
Gross Profit	155.84M	-64.67M	66.05M	-52.81M	-35.83M
EBITDA	34.46M	-88.93M	50.04M	-83.56M	-64.44M
Net Income	15.22M	-96.99M	37.51M	-95.06M	-229.35M
Balance Sheet
Total Assets	696.15M	509.96M	407.82M	174.65M	254.65M
Cash, Cash Equivalents and Short-Term Investments	604.45M	425.89M	362.20M	145.12M	231.98M
Total Debt	16.20M	15.40M	14.56M	9.85M	6.19M
Total Liabilities	121.30M	284.88M	194.66M	150.58M	150.39M
Stockholders Equity	574.84M	225.08M	213.16M	24.06M	104.26M
Cash Flow
Free Cash Flow	-174.51M	-12.73M	93.92M	-87.44M	-93.13M
Operating Cash Flow	-158.03M	18.23M	100.13M	-81.78M	-85.61M
Investing Cash Flow	-152.39M	-31.39M	-209.79M	7.49M	-15.95M
Financing Cash Flow	319.68M	84.52M	123.71M	-2.61M	207.88M

Immatics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMTX, the sentiment is Positive. The current price of 6.13 is above the 20-day moving average (MA) of 5.72, above the 50-day MA of 5.45, and below the 200-day MA of 6.35, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 61.92 is Neutral, neither overbought nor oversold. The STOCH value of 82.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMTX.

Immatics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCYC	60 Neutral	$531.47M	―	-37.13%	―	-38.14%	29.69%
IMTX	58 Neutral	$745.10M	53.85	-4.52%	―	92.31%	78.17%
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
QURE	50 Neutral	$764.29M	―	-241.16%	―	6.30%	29.17%
KURA	47 Neutral	$552.35M	―	-41.84%	―	―	3.95%
SVRA	46 Neutral	$395.80M	―	-75.77%	―	―	-44.25%
COGT	37 Underperform	$1.94B	―	-84.04%	―	―	-2.53%